Albemarle Co. (ALB) Earns “Buy” Rating from Royal Bank of Canada

Royal Bank of Canada reissued their buy rating on shares of Albemarle Co. (NYSE:ALB) in a research note published on Tuesday. They currently have a $132.00 price target on the specialty chemicals company’s stock.

ALB has been the subject of several other research reports. Jefferies Group LLC reissued a buy rating and issued a $120.00 price objective (up previously from $105.00) on shares of Albemarle in a research note on Wednesday, March 1st. Robert W. Baird raised shares of Albemarle from a neutral rating to an outperform rating and raised their price objective for the company from $81.00 to $118.00 in a research note on Tuesday, January 17th. Instinet raised their price objective on shares of Albemarle from $102.00 to $118.00 and gave the company a buy rating in a research note on Wednesday, March 1st. Aegis assumed coverage on shares of Albemarle in a research note on Friday, February 17th. They issued a buy rating and a $108.00 price objective for the company. Finally, Zacks Investment Research raised shares of Albemarle from a hold rating to a buy rating and set a $117.00 price objective for the company in a research note on Monday, March 27th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Albemarle has an average rating of Buy and an average price target of $111.00.

Analyst Recommendations for Albemarle (NYSE:ALB)

Shares of Albemarle (NYSE:ALB) opened at 105.52 on Tuesday. Albemarle has a 52-week low of $65.57 and a 52-week high of $107.56. The stock has a market capitalization of $11.88 billion, a PE ratio of 18.56 and a beta of 1.41. The firm has a 50-day moving average of $104.69 and a 200 day moving average of $92.26.

Albemarle (NYSE:ALB) last posted its quarterly earnings data on Monday, February 27th. The specialty chemicals company reported $0.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.05. Albemarle had a net margin of 6.92% and a return on equity of 14.38%. The business earned $696.70 million during the quarter, compared to analyst estimates of $642.68 million. During the same quarter last year, the firm posted $1.03 earnings per share. The business’s revenue for the quarter was down 3.6% compared to the same quarter last year. Equities research analysts forecast that Albemarle will post $4.18 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/04/21/albemarle-co-alb-earns-buy-rating-from-royal-bank-of-canada.html.

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 3rd. Shareholders of record on Wednesday, March 15th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Monday, March 13th. This represents a $1.28 dividend on an annualized basis and a yield of 1.21%. This is a boost from Albemarle’s previous quarterly dividend of $0.31. Albemarle’s dividend payout ratio (DPR) is presently 63.54%.

Hedge funds have recently added to or reduced their stakes in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. bought a new stake in Albemarle during the third quarter worth $104,000. Creative Planning boosted its stake in Albemarle by 16.8% in the third quarter. Creative Planning now owns 1,228 shares of the specialty chemicals company’s stock worth $105,000 after buying an additional 177 shares during the last quarter. Van ECK Associates Corp boosted its stake in Albemarle by 97.7% in the fourth quarter. Van ECK Associates Corp now owns 1,360 shares of the specialty chemicals company’s stock worth $117,000 after buying an additional 672 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Albemarle by 0.3% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 1,443 shares of the specialty chemicals company’s stock worth $123,000 after buying an additional 5 shares during the last quarter. Finally, Cullinan Associates Inc. bought a new stake in Albemarle during the first quarter worth $201,000. 86.50% of the stock is currently owned by institutional investors.

Albemarle Company Profile

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

5 Day Chart for NYSE:ALB

Receive News & Ratings for Albemarle Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply